FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W76887270> ?p ?o ?g. }

• W76887270 abstract "Abstract High dose melphalan conditioned APBSCT after induction therapy is thestandard of carefor patients with myeloma with good performance status. Busy haematology units are in the lookout for safe and effective strategies to hasten neutrophil engraftment, decrease inpatient stay and ease financial burden. Growth factors have been helpful in this regard. We describe our experience with the use of different growth factors in patients with myeloma undergoing APBSCT. Aims of the study To identify whether once daily lenograstimfrom day + 7 following APBSCT is as efficacious as one dose of pegfilgrastim on day +1with regards to neutrophil engraftment, inpatient stay, days of antibiotic use and outcomes as compared no G-CSF use. Materials and Methods Patients had induction treatment followed by autologous PBSC mobilisation with G-CSF alone or by cyclophosphamide (3g/m2) + G-CSF schedule. APBSCT with high dose melphalan (140 or 200 mg/ m2) conditioning was carried out as per standard indications and the day of stem cell re-infusion was termed day 0. Statistical analysis was carried out using GraphPad Prism 4 and IBM SPSS 19 for Windows. Our retrospective study included 112 patients (71male&41 female) with a median age at transplantation of 61 years (range 38-72) with myeloma betweenJanuary2006 and December 2012. 35%patients did not receive any G-CSF, 19% received pegfilgrastim and46% received lenograstim.58 % patients had IgG, 21 % IgA, 17 % light chain and 4 % had non-secretory myeloma. At transplant 7% patients were in complete remission, 20% in partial remission and 73% in very good partial remission. Results Median time for neutrophil engraftment was 14, 12 and 13 days in the no G-CSF, peg-filgrastim and lenograstim respectively. Median inpatient stay was 18, 16 and 16 days in the no G-CSF, peg-filgrastim and lenograstim respectively. Median days of broad spectrum intravenous antibiotic use were 6, 5 and 5 days in the no G-CSF, peg-filgrastim and lenograstim respectively. Median dose of stem cells infused was 3.1, 2.7 and 2.5 CD 34 + cells per kg body weight in the no G-CSF, peg-filgrastim and lenograstim respectively.There was no difference in the overall survival (Log Rank test; p value: 0.844) or progression free survival (Log Rank test; p value: 0.155) between the three cohorts. Summary Results of retrospective analysis suggests that the use of daily lenograstim from day +7 is an effective strategy as day + 1 peg-filgrastim in patients with myeloma undergoing APBSCTin reducing the time to neutrophil engraftment, duration of inpatient stay and antibiotic useand superior to no G-CSF use. Our data confirms daily lenograstim from day +7 is a cost effective alternative strategy to pegfilgrastimmaking use of use of lenograstim post autologous stem cell transplantation as a standard practice. Disclosures: No relevant conflicts of interest to declare." @default.
• W76887270 created "2016-06-24" @default.
• W76887270 creator A5002161189 @default.
• W76887270 creator A5008403602 @default.
• W76887270 creator A5016718675 @default.
• W76887270 creator A5043665917 @default.
• W76887270 creator A5043708379 @default.
• W76887270 creator A5053124814 @default.
• W76887270 creator A5064080209 @default.
• W76887270 creator A5066113444 @default.
• W76887270 creator A5072008697 @default.
• W76887270 creator A5076959509 @default.
• W76887270 creator A5082257769 @default.
• W76887270 date "2013-11-15" @default.
• W76887270 modified "2023-10-13" @default.
• W76887270 title "Is Daily Lenograstim From Day +7 Of Autologous Peripheral Blood Stem Cell Transplantation (APBSCT) Is As Effective As Pegfilgrastim In Patients With Myeloma?" @default.
• W76887270 doi "https://doi.org/10.1182/blood.v122.21.5538.5538" @default.
• W76887270 hasPublicationYear "2013" @default.
• W76887270 type Work @default.
• W76887270 sameAs 76887270 @default.
• W76887270 citedByCount "0" @default.
• W76887270 crossrefType "journal-article" @default.
• W76887270 hasAuthorship W76887270A5002161189 @default.
• W76887270 hasAuthorship W76887270A5008403602 @default.
• W76887270 hasAuthorship W76887270A5016718675 @default.
• W76887270 hasAuthorship W76887270A5043665917 @default.
• W76887270 hasAuthorship W76887270A5043708379 @default.
• W76887270 hasAuthorship W76887270A5053124814 @default.
• W76887270 hasAuthorship W76887270A5064080209 @default.
• W76887270 hasAuthorship W76887270A5066113444 @default.
• W76887270 hasAuthorship W76887270A5072008697 @default.
• W76887270 hasAuthorship W76887270A5076959509 @default.
• W76887270 hasAuthorship W76887270A5082257769 @default.
• W76887270 hasConcept C126322002 @default.
• W76887270 hasConcept C141071460 @default.
• W76887270 hasConcept C143998085 @default.
• W76887270 hasConcept C194409129 @default.
• W76887270 hasConcept C2776364478 @default.
• W76887270 hasConcept C2776694085 @default.
• W76887270 hasConcept C2776755627 @default.
• W76887270 hasConcept C2777063308 @default.
• W76887270 hasConcept C2777767877 @default.
• W76887270 hasConcept C2778658803 @default.
• W76887270 hasConcept C2778684742 @default.
• W76887270 hasConcept C2779171977 @default.
• W76887270 hasConcept C2911091166 @default.
• W76887270 hasConcept C71924100 @default.
• W76887270 hasConcept C74133956 @default.
• W76887270 hasConceptScore W76887270C126322002 @default.
• W76887270 hasConceptScore W76887270C141071460 @default.
• W76887270 hasConceptScore W76887270C143998085 @default.
• W76887270 hasConceptScore W76887270C194409129 @default.
• W76887270 hasConceptScore W76887270C2776364478 @default.
• W76887270 hasConceptScore W76887270C2776694085 @default.
• W76887270 hasConceptScore W76887270C2776755627 @default.
• W76887270 hasConceptScore W76887270C2777063308 @default.
• W76887270 hasConceptScore W76887270C2777767877 @default.
• W76887270 hasConceptScore W76887270C2778658803 @default.
• W76887270 hasConceptScore W76887270C2778684742 @default.
• W76887270 hasConceptScore W76887270C2779171977 @default.
• W76887270 hasConceptScore W76887270C2911091166 @default.
• W76887270 hasConceptScore W76887270C71924100 @default.
• W76887270 hasConceptScore W76887270C74133956 @default.
• W76887270 hasLocation W768872701 @default.
• W76887270 hasOpenAccess W76887270 @default.
• W76887270 hasPrimaryLocation W768872701 @default.
• W76887270 hasRelatedWork W2054954620 @default.
• W76887270 hasRelatedWork W2102204740 @default.
• W76887270 hasRelatedWork W2118109429 @default.
• W76887270 hasRelatedWork W2182583492 @default.
• W76887270 hasRelatedWork W2276500441 @default.
• W76887270 hasRelatedWork W2376402404 @default.
• W76887270 hasRelatedWork W2528447728 @default.
• W76887270 hasRelatedWork W2532599497 @default.
• W76887270 hasRelatedWork W2554918308 @default.
• W76887270 hasRelatedWork W2560311360 @default.
• W76887270 hasRelatedWork W2571962685 @default.
• W76887270 hasRelatedWork W2578530988 @default.
• W76887270 hasRelatedWork W2587715748 @default.
• W76887270 hasRelatedWork W2588633943 @default.
• W76887270 hasRelatedWork W2804325849 @default.
• W76887270 hasRelatedWork W2980138379 @default.
• W76887270 hasRelatedWork W3002313124 @default.
• W76887270 hasRelatedWork W3014729529 @default.
• W76887270 hasRelatedWork W3140315359 @default.
• W76887270 hasRelatedWork W2128374816 @default.
• W76887270 isParatext "false" @default.
• W76887270 isRetracted "false" @default.
• W76887270 magId "76887270" @default.
• W76887270 workType "article" @default.